• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH Studying Approved and Investigational Therapies for Use Against COVID-19

NIH Studying Approved and Investigational Therapies for Use Against COVID-19

October 19, 2020

The National Institute of Allergy and Infectious Diseases (NIAID) has begun a phase 2 study of the potential of approved therapies and late-stage investigational drugs for hospitalized COVID-19 patients.

The study, termed the ACTIV-5 Big Effect Trial (ACTIV-5/BET), is enrolling adults with COVID-19 at up to 40 sites in the U.S. It is being conducted in partnership with the National Institutes of Health’s Accelerating COVID-19 Therapeutic Innovations and Vaccines (ACTIV) program.

In the randomized ACTIV-5/BET trial, licensed drugs and investigational therapies that show promise against COVID-19 compared with controls will be propelled into larger COVID-19 trials. Around 100 hospitalized patients will be randomly assigned to each study arm. No more than three investigational therapies will be tested at once.

The first candidate to be tested in the trial includes monoclonal antibody risankizumab from Boehringer Ingelheim and AbbVie. This drug is currently FDA-approved for severe plaque psoriasis, but ACTIV-5/BET will test it in combination with remdesivir vs. placebo.

ACTIV-5/BET will also test lenzilumab, Humanigen’s late-stage investigational drug for the prevention and treatment of cytokine storm, in combination with remdesivir. 

COVID-19
  • Related Directories

    Veklury (remdesivir)

    Pfizer-BioNtech COVID-19 Vaccine

    Moderna COVID-19 Vaccine (mRNA-1273)

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing